| xReality Group Ltd (XRG) ORDINARY FULLY PAID |
Consumer Discretionary |
$48 |
Successful completion of DoD project
|
15 May 2026 8:26AM |
$0.056 |
$0.064 |
risen by
14.29%
|
|
XRG - Price-sensitive ASX Announcement
Full Release
Key Points
- Successful completion of AU$5.6 million subcontract with US Department of Defense.
- Development and commercialization of MR-1 mixed reality training system.
- MR-1 system allows overlaying virtual elements onto real-world environments.
- First commercial sale of MR-1 to a separate US Department of Defense customer.
- Project completed on time and within budget.
- Potential for broader application in defense and law enforcement sectors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Catalyst Metals Limited (CYL) ORDINARY FULLY PAID |
Materials |
$1,310 |
Drilling at Old Highway confirms resource growth potential
|
15 May 2026 8:25AM |
$5.860 |
$5.020 |
fallen by
14.33%
|
|
CYL - Price-sensitive ASX Announcement
Full Release
Key Points
- Catalyst Metals Limited has reported significant drilling results from the Old Highway gold deposit.
- The deposit is located 40km south of the Plutonic processing plant and has resources of 206koz at 3.0 g/t Au.
- The drilling aims to expand resource growth potential and extend mine life beyond the current four years.
- Significant drill intercepts include results of 6m @ 4.1g/t Au and 12m @ 3.7g/t Au.
- Development plans for Old Highway include a transition from a small open pit to a high-grade underground mine.
- Old Highway is part of Catalyst's strategy to increase production at the Plutonic Gold Belt from ±100koz to ±200koz annually.
- The project sits within a broader 4km mineralized trend, creating opportunities for further discoveries.
- Catalyst is working on approvals for the development of Old Highway in line with its expected timeline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bioxyne Limited (BXN) ORDINARY FULLY PAID |
Consumer Staple |
$197 |
Change of Director's Interest Notice
|
15 May 2026 8:25AM |
$0.084 |
$0.086 |
risen by
2.38%
|
|
| Zip Co Limited (ZIP) ORDINARY FULLY PAID |
Financials |
$3,336 |
Update - Notification of buy-back - ZIP
|
15 May 2026 8:25AM |
$2.400 |
$2.660 |
risen by
10.83%
|
|
| Janus Electric Holdings Limited (JNS) ORDINARY FULLY PAID |
Utilities |
$20 |
Application for quotation of securities - JNS
|
15 May 2026 8:25AM |
$0.220 |
$0.155 |
fallen by
29.55%
|
|
| MoneyMe Limited (MME) ORDINARY FULLY PAID |
Financials |
$66 |
MONEYME Executes $365.4m Personal Loan ABS Transaction
|
15 May 2026 8:25AM |
$0.084 |
$0.081 |
fallen by
3.57%
|
|
| Fat Prophets Global Contrarian Fund Limited (FPC) ORDINARY FULLY PAID |
Financials |
$41 |
Net Tangible Asset Backing
|
15 May 2026 8:25AM |
$1.490 |
$1.355 |
fallen by
9.06%
|
|
| hipages Group Holdings Limited (HPG) ORDINARY FULLY PAID |
Communication Services |
$105 |
Update - Notification of buy-back - HPG
|
15 May 2026 8:25AM |
$0.735 |
$0.765 |
risen by
4.08%
|
|
| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$13,687 |
FY26 Full Year - Key Dates
|
15 May 2026 8:25AM |
$4.590 |
$4.970 |
risen by
8.28%
|
|
| Dateline Resources Limited (DTR) ORDINARY FULLY PAID |
Materials |
$440 |
Underground Gold Potential Grows at Colosseum
|
15 May 2026 8:25AM |
$0.200 |
$0.115 |
fallen by
42.50%
|
|
DTR - Price-sensitive ASX Announcement
Full Release
Key Points
- Gold mineralization extended at Colosseum North Pit.
- Significant drill intersections: CM25-41 and CM26-42.
- Possibility of an underground deposit following open-pit mining.
- Expansion of the REE drilling program to 18 holes.
- High specific gravity rocks discovered, indicating potential.
- Positive economic outcomes for Colosseum Gold Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mammoth Minerals Limited (M79) ORDINARY FULLY PAID |
Materials |
$24 |
Nevada Gold and Silver results highlight growth potential
|
15 May 2026 8:25AM |
$0.067 |
$0.043 |
fallen by
35.82%
|
|
M79 - Price-sensitive ASX Announcement
Full Release
Key Points
- Exploration results show high-grade gold and silver mineralization.
- Blue Dick sampling defines multiple high-grade mineral trends.
- Buster Gold Trend drilling supports a Carlin-type deposit model.
- Mammoth finalizing data for a Mineral Resource Estimate.
- Strategic acquisitions enhance Mammoth's growth in Nevada.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ansell Limited (ANN) ORDINARY FULLY PAID |
Health Care |
$4,121 |
Update - Notification of buy-back - ANN
|
15 May 2026 8:25AM |
$25.710 |
$29.270 |
risen by
13.85%
|
|
| Argo Investments Limited (ARG) ORDINARY FULLY PAID |
Financials |
$6,541 |
Update - Notification of buy-back - ARG
|
15 May 2026 8:25AM |
$8.720 |
$8.680 |
fallen by
0.46%
|
|
| James Hardie Industries Plc (JHX) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$11,367 |
APPENDIX 3Z - P LISBOA
|
15 May 2026 8:24AM |
$27.030 |
$33.580 |
risen by
24.23%
|
|
| Boom Logistics Limited (BOL) ORDINARY FULLY PAID |
Industrials |
$74 |
Update - Notification of buy-back - BOL
|
15 May 2026 8:24AM |
$1.780 |
$2.000 |
risen by
12.36%
|
|
| REA Group Ltd (REA) ORDINARY FULLY PAID |
Communication Services |
$18,750 |
Update - Notification of buy-back - REA
|
15 May 2026 8:24AM |
$161.240 |
$143.000 |
fallen by
11.31%
|
|
| James Hardie Industries Plc (JHX) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$11,367 |
Appointment of New Non-Executive Director
|
15 May 2026 8:24AM |
$27.030 |
$33.580 |
risen by
24.23%
|
|
| Bravura Solutions Limited (BVS) ORDINARY FULLY PAID |
Information Technology |
$1,004 |
Initial Director's Interest Notice
|
15 May 2026 8:24AM |
$2.160 |
$2.240 |
risen by
3.70%
|
|
| Peoplein Limited (PPE) ORDINARY FULLY PAID |
Industrials |
$71 |
Update - Notification of buy-back - PPE
|
15 May 2026 8:24AM |
$0.560 |
$0.650 |
risen by
16.07%
|
|
| Nova Minerals Limited (NVA) ORDINARY FULLY PAID |
Materials |
$350 |
Cleansing Statement
|
15 May 2026 8:24AM |
$0.700 |
$0.765 |
risen by
9.29%
|
|
| Nova Minerals Limited (NVA) ORDINARY FULLY PAID |
Materials |
$350 |
Application for quotation of securities - NVA
|
15 May 2026 8:24AM |
$0.700 |
$0.765 |
risen by
9.29%
|
|
| Capral Limited (CAA) ORDINARY FULLY PAID |
Materials |
$183 |
Update - Notification of buy-back - CAA
|
15 May 2026 8:23AM |
$12.190 |
$11.490 |
fallen by
5.74%
|
|
| AVITA Medical, Inc. (AVH) CHESS DEPOSITARY INTERESTS 5:1 |
Health Care |
$93 |
Financial Results for Quarter Ending 31 March 2026
|
15 May 2026 8:23AM |
$1.200 |
$1.080 |
fallen by
10%
|
|
AVH - Price-sensitive ASX Announcement
Full Release
Key Points
- AVITA Medical, Inc. reported a net loss of $10.6 million for the quarter ending March 31, 2026, compared to a loss of $13.9 million in the previous year.
- The company’s total revenue increased to $19.25 million from $18.51 million in the prior year, with significant contributions from commercial sales.
- Operating expenses decreased from $27.5 million to $24.5 million, driven by reductions in sales and marketing expenses.
- The company recorded comprehensive losses of $8.6 million, down from $12.3 million the previous year, partly due to changes in the fair value of financial instruments.
- AVITA’s cash and cash equivalents totaled $8.3 million as of March 31, 2026, with an additional $6 million in marketable securities.
- The company has liabilities of $74.7 million, including a loan facility valued at $46.1 million and warrant liabilities of $2.2 million.
- AVITA issued 144,895 shares of common stock due to the exercise of penny warrants and recorded stock-based compensation of $1.1 million.
- The company operates primarily in the United States, with substantial revenue generated from its RECELL product line.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AVITA Medical, Inc. (AVH) CHESS DEPOSITARY INTERESTS 5:1 |
Health Care |
$93 |
AVITA Medical Q1 2026 Earnings Presentation
|
15 May 2026 8:23AM |
$1.200 |
$1.080 |
fallen by
10%
|
|
AVH - Price-sensitive ASX Announcement
Full Release
Key Points
- Q1 2026 net revenue of USD 19.3 million.
- Gross profit margin of 81.7%.
- Cohealyx reduces time to skin grafting by ~20 days.
- Positive surgeon validation for Cohealyx.
- Secured a 10-year BARDA deal for U.S. burn preparedness.
- Reaffirmed 2026 net revenue guidance of USD 80 to 85 million.
- 12% to 19% growth over 2025 expected.
- Consistent procedure-driven demand for RECELL products.
- Positioned for continued quarterly growth in 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AVITA Medical, Inc. (AVH) CHESS DEPOSITARY INTERESTS 5:1 |
Health Care |
$93 |
AVITA Medical Reports First Quarter 2026 Financial Results
|
15 May 2026 8:23AM |
$1.200 |
$1.080 |
fallen by
10%
|
|
AVH - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue for the first quarter of 2026 was approximately $19.3 million, a 4% increase year-over-year.
- The company's gross profit margin was 81.7%, down slightly from 84.7% the previous year due to product mix changes.
- Operating expenses decreased by 11% year-over-year to $24.5 million, reflecting cost optimization measures.
- Net loss for the quarter was $10.6 million, or $0.35 per share, compared to a net loss of $13.9 million, or $0.53 per share, in the same period in 2025.
- AVITA Medical secured a 10-year BARDA agreement valued at up to $25.5 million for U.S. burn emergency preparedness.
- Positive interim data from Cohealyx I showed a significant reduction in time to skin grafting readiness, supporting clinical outcomes.
- The company received regulatory clearance for RECELL GO® in Australia and New Zealand.
- Expected full-year 2026 revenue is in the range of $80 to $85 million, reflecting 12% to 19% growth over 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.